Immune cell therapy for CD70-positive blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This early study tests a new type of immune cell treatment (called JY306 NK cells) for people with blood cancers that have relapsed or not responded to treatment. The treatment targets a marker on cancer cells called CD70 to try to destroy them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a blood cancer (like leukemia, lymphoma, or myeloma) that has come back or hasn't responded to standard treatment.
- Your cancer cells show a high level of a specific marker called CD70 (higher than 80%).
- You are able to care for yourself and are fairly active (KPS score of 80 or higher).
- Your vital organs (like heart, lungs, liver, and kidneys) are working well enough.
- You don't have other major medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
Hear when a new Relapsed or Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.